CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
Rhea-AI Summary
CVRx (NASDAQ: CVRX) will release its first quarter 2026 financial and operating results after market close on Monday, May 11, 2026. The company will host a conference call at 4:30 p.m. ET the same day with a live webcast on its investor relations site.
Telephone dial-in numbers for the call are provided for U.S. and international callers; listeners are asked to dial in about ten minutes early.
Positive
- None.
Negative
- None.
News Market Reaction – CVRX
In the Apr 28 session, CVRX declined 2.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Earnings date notice | Neutral | -2.3% | Announced Q4 2025 results release timing and related conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news led to a modest negative move of -2.28%, suggesting these timing announcements have had limited impact.
Recent CVRx news centered on financial performance, clinical progress, and governance. A January 2026 announcement setting the Q4 2025 earnings date and call details (news_id 1005786) saw a -2.28% move, implying limited trading impact from logistics-focused releases. By contrast, preliminary Q1 2026 results and clinical updates have driven larger price reactions. Today’s Q1 2026 earnings date notice fits the pattern of operational scheduling rather than new financial data.
Key Terms
neuromodulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release first quarter 2026 financial and operating results after market close on Monday, May 11, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
